1Luoyang Orthopedic Hospital of Henan Province, Orthopedic Institute of Henan Province, Luoyang 471002, China
2Shanghai First Maternity and Infant Hospital, Tongji University of Medicine. Shanghai, 200126, China
3Henan University of Traditional Chinese Medicine, Henan Province, Zhengzhou 450000, China
4Medical Science & Research Center, Beijing Shijitan Hospital Affiliated to Capital Medical University, 10 Tieyi Road, Beijing 100038, China
Objective(s): Naringin has been reported to regulate bone metabolism. However, its effect on osteogenesis remains unclear. The aim was to investigate the effect of naringin on osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMSCs) through the activation of the ERK signaling pathway in osteogenic differentiation. Materials and Methods: Annexin V-FITC assay and MTT assay were used to measure the effect of naringin on cytotoxicity and proliferation of hBMSCs, respectively. Alkaline phosphatase activity analysis, Alizarin Red S staining, Western blotting, and real-time PCR assay were used to evaluate both the potential effect of naringin on osteogenic differentiation and the role of ERK signaling pathway in osteogenic differentiation. Results: Our results showed that naringin had no obvious toxicity on hBMSCs, and could significantly promote the proliferation of hBMSCs. Naringin also enhanced the osteogenic differentiation of hBMSCs and increased the protein and mRNA expression levels of osteogenic markers such as Runx-2, OXS, OCN, and Col1 in a dose-dependent manner. In addition, we found that the enhancing effect of naringin on osteogenic differentiation was related to the activation of phosphor-ERK, with an increase in duration of activity from 30 min to 120 min. More importantly, both the enhancing effect of naringin on osteogenic differentiation and the activity effect of naringin on ERK signaling pathway were reversed by U0126 addition. Conclusion: Our findings demonstrated that naringin promoted proliferation and osteogenesis of hBMSCs by activating the ERK signaling pathway and it might be a potential therapeutic agent for treating or preventing osteoporosis.
2.Drake MT, Clarke BL, Lewiecki EM. The Pathophysiology and Treatment of Osteoporosis. Clin Ther 2015; 37:1837-1850.
3.Lim SY, Bolster MB. Current approaches to osteoporosis treatment. Curr Opin Rheumatol 2015; 27:216-224.
4.James AW. Review of Signaling Pathways Governing MSC Osteogenic and Adipogenic Differentiation. Scientifica 2013; 2013:684736.
5.Bidwell JP, Alvarez MB, Hood M, Jr., Childress P. Functional impairment of bone formation in the pathogenesis of osteoporosis: the bone marrow regenerative competence. Curr Osteoporos Rep 2013; 11:117-125.
6.Guan M, Yao W, Liu R, Lam KS, Nolta J, Jia J, et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med 2012; 18:456-462.
7.McArthur GA. Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet. Front Oncol 2015; 5:161.
8.Ying X, Cheng S, Wang W, Lin Z, Chen Q, Zhang W, et al. Effect of lactoferrin on osteogenic differentiation of human adipose stem cells. Int Orthop 2012; 36:647-653.
9.Gonzalez-Andrades MG, I., Alaminos M. Advances in the Field of Tissue Engineering and Regenerative Medicine: State of the Art and Regulatory Issues. J Biomater Tissue Eng 2013; 3:245-260.
10.Li Y, Wang J, Chen G, Feng S, Wang P, Zhu X, et al. Quercetin promotes the osteogenic differentiation of rat mesenchymal stem cells via mitogen-activated protein kinase signaling. Exp Ther Med 2015; 9:2072-2080.
11.Zhou C, Zhang X, Xu L, Wu T, Cui L, Xu D. Taurine promotes human mesenchymal stem cells to differentiate into osteoblast through the ERK pathway. Amino Acids 2014; 46:1673-1680.
12.Xu D, Xu L, Zhou C, Lee WY, Wu T, Cui L, et al. Salvianolic acid B promotes osteogenesis of human mesenchymal stem cells through activating ERK signaling pathway. Int J Biochem Cell Biol 2014; 51:1-9.
13.Kim JM, Lee JE, Ryu SH, Suh PG. Chlormadinone acetate promotes osteoblast differentiation of human mesenchymal stem cells through the ERK signaling pathway. Euro J Pharmacol 2014; 726:1-8.
14.Bharti S, Rani N, Krishnamurthy B, Arya DS.
Preclinical evidence for the pharmacological actions of naringin: a review. Planta Med 2014; 80:437-451.
15.Li F, Sun X, Ma J, Ma X, Zhao B, Zhang Y, et al. Naringin prevents ovariectomy-induced osteoporosis and promotes osteoclasts apoptosis through the mitochondria-mediated apoptosis pathway. Biochem Biophys Res Commun 2014; 452:629-635.
16.Li N, Xu Z, Wooley PH, Zhang J, Yang SY. Therapeutic potentials of naringin on polymethylmethacrylate induced osteoclastogenesis and osteolysis, in vitro and in vivo assessments. Drug Des Devel Ther 2014; 8:1-11.
17.Zhang P, Dai KR, Yan SG, Yan WQ, Zhang C, Chen DQ, et al. Effects of naringin on the proliferation and osteogenic differentiation of human bone mesenchymal stem cell. Euro J Pharmacol 2009; 607:1-5.
18.Baharara J, Amini E, Kerachian MA, Soltani M. The osteogenic differentiation stimulating activity of Sea cucumber methanolic crude extraction on rat bone marrow mesenchymal stem cells. Iran J Basic Med Sci 2014; 17:626-631.
19. Fang B, Wan YZ, Tang TT, Gao C, Dai KR. Proliferation and osteoblastic differentiation of human bone marrow stromal cells on hydroxyapatite/bacterial cellulose nanocomposite scaffolds. Tissue Eng Part A 2009;15:1091-1098.
20. Hou X, Shen Y, Zhang C, Zhang L, Qin Y, Yu Y, et al. A specific oligodeoxynucleotide promotes the differentiation of osteoblasts via ERK and p38 MAPK pathways. Int J Mol Sci 2012; 13:7902-7914.
21. Jagetia GC, Reddy TK, Venkatesha VA, Kedlaya R. Influence of naringin on ferric iron induced oxidative damage in vitro. Clin Chim Acta 2004; 347:189-197.
22.Liu Y, Su WW, Wang S, Li PB. Naringin inhibits chemokine production in an LPS-induced RAW 264.7 macrophage cell line. Mol Med Rep 2012; 6:1343-1350.
23.Pang WY, Wang XL, Mok SK, Lai WP, Chow HK, Leung PC, et al. Naringin improves bone properties in ovariectomized mice and exerts oestrogen-like activities in rat osteoblast-like (UMR-106) cells. Br J Pharmacol 2010; 159:1693-1703.
24.Li L, Zeng Z, Cai G. Comparison of neoeriocitrin and naringin on proliferation and osteogenic differentiation in MC3T3-E1. Phytomedicine 2011; 18:985-989.
25.Liu M, Li Y, Yang ST. Effects of naringin on the proliferation and osteogenic differentiation of human amniotic fluid-derived stem cells. J Tissue Eng Regen Med 2014:doi: 10.1002/term.1911.
26.Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89:755-764.
27.Potier E, Noailly J, Ito K. Directing Bone marrow-derived stromal cell function with mechanics. J Biomech 2010;43:807-817.
28. Miraoui H, Oudina K, Petite H, Tanimoto Y, Moriyama K, Marie PJ. Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling. J Biol Chem 2009; 284:4897-4904.
29.Xu C, Zheng Z, Fang L, Zhao N, Lin Z, Liang T, et al. Phosphatidylserine enhances osteogenic differentiation in human mesenchymal stem cells via ERK signal pathways. Mater Sci Eng C Mater Biol Appl 2013; 33:1783-1788.